Y.D. More Investments Ltd Sells 318,077 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Y.D. More Investments Ltd reduced its position in OPKO Health, Inc. (NASDAQ:OPK) by 18.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,395,768 shares of the biotechnology company’s stock after selling 318,077 shares during the quarter. Y.D. More Investments Ltd’s holdings in OPKO Health were worth $2,059,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in OPK. PFG Investments LLC grew its position in OPKO Health by 9.4% in the fourth quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock valued at $1,707,000 after acquiring an additional 99,795 shares during the last quarter. World Investment Advisors LLC bought a new stake in shares of OPKO Health during the 3rd quarter valued at approximately $61,000. Virtu Financial LLC bought a new position in OPKO Health in the 3rd quarter valued at approximately $120,000. Barclays PLC lifted its stake in shares of OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after acquiring an additional 329,870 shares during the last quarter. Finally, Orion Portfolio Solutions LLC bought a new position in OPKO Health in the third quarter valued at about $45,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the acquisition, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have bought 2,001,792 shares of company stock valued at $3,054,984. 47.26% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on OPK shares. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th.

OPKO Health Stock Up 4.0 %

Shares of OPK opened at $1.56 on Wednesday. The business has a 50-day moving average of $1.52 and a 200-day moving average of $1.52. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $1.76.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $173.60 million during the quarter, compared to analyst estimates of $181.32 million. During the same quarter last year, the business earned ($0.11) EPS. Equities research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.